the underlying assumptions in the model that warrants further discussion; namely, the proposed function to describe changes in CL/F with age.
In Fig. 1 we have plotted the change in predicted values of CL/F with post-natal age (PNA) as reported by the authors, using a continuous function to predict typical weight for age [3] . Here it can be seen that CL/F peaks at a post-menstrual age (PMA) of approximately 110 weeks (PNA of 1.3 years), then declines, and does not reach the same rate again until approximately 280 weeks PMA (PNA of 4.6 years). Between us we have extensive experience of modelling pharmacokinetic studies over large age ranges [4] [5] [6] [7] [8] , analysed how clearance in general changes for thousands of hypothetical drugs (e.g. see Calvier et al. [9] ), and systematically reviewed clearance maturation functions in children [10, 11] . The authors describe an extremely rare (possibly the first) case of decreasing CL/F with increasing age in infants and young children. Since CL/F determines steady-state concentration, and in this case maintenance dose, it is important that this change in CL/F with age is further explored. There are several possible explanations:
Firstly, the arbitrary step function used to describe decreasing CL/F with age above 65 years may be causing an under-estimation of the true young adult value, and hence the dematuration function the authors report is merely a result of this under-estimate exacerbated by limited data in children aged 4-12 years. A more granular breakdown of goodness-of-fit to age groups of < 1, 1-2, 3-4 and 12-30 years would show whether model fit was consistent amongst each age group.
A second possibility is that bioavailability (F) is for some reason lower in infants taking the immediate release formulation, consequently making CL/F seem high. This seems unlikely since immediate-and extended-release formulations have been reported to be bioequivalent [12] , and lamotrigine is generally well-absorbed, but changes in F with age cannot be ruled out.
A third possibility, and one we think most likely, is that drug-drug interactions are causing confounding given that different age groups had different co-medication frequencies. Re-fitting the model to data only in patients not taking carbamazepine, phenytoin or valproic acid and re-evaluating maturation parameters would determine this. Such an analysis would give confidence that the relative contribution of maturation and drug-drug interactions are correctly captured by the model. Further insight may also be achieved through physiologically based pharmacokinetic analysis, which may predict how CL/F could change with both age and in the presence of drug-drug interactions.
This finding of decreasing CL/F with increasing age in infants and young children is a novel unexpected result, and further exploration to confirm whether it is a real phenomenon, and if so why it happens with lamotrigine, is required.
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